To explore the effect and mechanism of pomalidomide on the immune activity of dendritic cell-derived exosomes (DEXs) from patients with multiple myeloma (MM). MoDCs were induced from monocytes obtained from patients with MM and HDs with or without pomalidomide treatment. DEXs were then isolated from culture supernatants via ultracentrifugation and characterized by TEM and NTA. Surface markers (CD63, CD81, CD80, CD86, and HLA-DR) were analyzed using nanoflow cytometry. Functional assays included coculturing DEXs with autologous PBMCs to activate T cells, followed by sorting CD8+ T cells and assessing their pro-apoptotic effect on U266 cells via flow cytometry. Mechanistic insights were explored through miRNA sequencing of DEXs and transcriptome sequencing of T cells. Pomalidomide significantly increased the proportion of DEXs derived from patients with multiple myeloma (MM) and increased the expression levels and mean fluorescence intensity (MFI) of surface activation markers, including CD80, CD86 and HLA-DR. Functional assays demonstrated that DEXs treated with pomalidomide promoted the generation of CD8+ T cells and markedly increased both early and total apoptosis rates in U266 cells. Mechanistically, miRNAomic analysis indicated that pomalidomide potentially facilitates T-cell activation by modulating signaling pathways such as the MAPK and PI3K-Akt pathways. Transcriptome profiling further verified that this treatment triggered substantial metabolic reprogramming in T cells and significantly activated pathways associated with T-cell activation. This study provides a new strategy for enhancing the activity of DEXs derived from patients with MM, with the potential to develop DEXs as an antitumor vaccine for MM.

Aim: To explore the modulatory effect of leonurine on monocyte-derived DCs (moDCs) from chronic myeloid leukemia (CML) patients. Methods: Peripheral blood was collected from 12 CML patients treated with imatinib and 12 healthy donors in vitro. Monocytes from peripheral blood mononuclear cells (PBMCs) were induced to monocytes derived dendritic cells (moDCs). During this incubation period, 1μM leonurine or the same volume of drug solvent was given to the moDCs. After the moDCs were harvested, the expression of maturation/activity-associated markers on moDCs were assessed by flow cytometry. In addition, the immune activation-associated cytokines secreted by moDCs were measured by enzyme-linked immunosorbent assay (ELISA). Results: 1. When HDs derived moDCs and CML patients derived moDCs were analyzed, the proportion of CD40+moDC, CD83+moDCand HLA-DR+moDCs in the total moDCs exhibited no statistically significant difference (p=0.114; p=0.932; p=0.7995). 2. When CML patients derived moDCs with or without leonurine administration were analyzed, the propotion of moDCs in the total harvested cells was significantly higher in the leonurine group than in the control group (p = 0.030). Meanwhile, the proportion of HLA-DR+moDC and proportion of HLA-DR+moDCs in total moDCs were significantly higher in the leonurine group than in the control group (p = 0.034; p = 0.778; p = 0.027). Moreover, IL-6 secretion from moDCs was significantly enhanced in the leonurine group than in the control group (p = 0.013). Conclusion: Compared with healthy donors, CML patients after imatinib therapy show no significant difference on the activity / maturation of moDCs. Leonurine significantly enhances the activity / maturation of CML patients derived moDCs, which is potential to be applied as a DC adjuvant in DC-based immunotherapy for CML patients.

Exosomes are extracellular vesicles of nanoscale, which represent the characteristics of the cells of origin. Tumor cell-derived exosomes (TEXs) obtain the characteristics of the tumor cells, which meanwhile transfer the various substances from the tumor cells to regulate the other cells and microenvironments. TEXs play an important role in the pathogenesis of tumors, which can promote the progression, metastasis and recurrence of tumors. Furthermore, TEXs also facilitate chemotherapy resistance and radiotherapy resistance of tumors. TEXs can be applied as biomarkers for the diagnosis of tumors as well as the differentiation of the subtypes and stages of tumors. TEXs also can be used in the evaluation of the prognosis and chemotherapy/radiotherapy resistance of tumors. For tumor therapy, TEXs can be utilized as potential targets, delivery carriers and tumor vaccines to hinder tumor progression. This review highlights the recent advances in the research and application of TEXs, which provides new ideas for the understanding and control of tumor diseases.

HR19042 is a novel, orally administered, targeted-release formulation of the topically active corticosteroid budesonide, developed to release active drug within the terminal ileum and indicated to reduced estimated glomerular filtration rate loss in adults with primary immunoglobulin A nephropathy. This randomized, single-dose, open-label, six-sequence, three-treatment crossover trial aimed to explore the pharmacokinetic (PK) of HR19042 in comparison with two other budesonide targeted-release formulations among healthy Chinese subjects. Plasma budesonide concentrations were measured via liquid chromatography with tandem mass spectrometry, and PK parameters were analyzed using non-compartmental methods. Eighteen subjects successfully completed the trial. The median Tlag and Tmax of HR19042 were 1.25 and 3.50 h shorter than those of Nefecon, respectively. The Cmax of HR19042 was approximately 1.9-fold higher than that of Nefecon and 1.4-fold higher than that of Budenofalk. Based on the AUC0-t determination, the relative bioavailability (F) of HR19042 was approximately 136.93% relative to Nefecon and 129.68% relative to Budenofalk. In vitro, the dissolution of HR19042 occurred 30 min earlier than that of Nefecon in the intestinal buffer medium. In conclusion, both in vivo and in vitro findings suggest that HR19042 exhibits a faster absorption rate and higher oral bioavailability.

Abstract Precise control of quantum structures in hybrid nanocrystals requires advancements in scientific methodologies. Here, on the design of tunable CsPbBr3/Cs4PbBr6 quantum dots are reported by developing a unique discrete phase transformation approach in Cs4PbBr6 nanocrystals. Unlike conventional hybrid systems that emit solely in the green region, this current strategy produces adjustable luminescence in the blue (450 nm), cyan (480 nm), and green (510 nm) regions with high photoluminescence quantum yields up to 45%, 60%, and 85%, respectively. Concentration‐dependent studies reveal that phase transformation mechanisms and the factors that drive CsBr removal occur at lower dilutions while the dissolution–recrystallization process dominates at higher dilutions. When the polymer‐CsPbBr3/Cs4PbBr6 integrated into a field‐effected transistor the resulting phototransistors featured enhanced photosensitivity exceeding 105, being the highest reported for an n‐type phototransistor, while maintaining good transistor performances as compared to devices consisting of polymer‐CsPbBr3 NCs.

Hematological malignancies originate from the hematopoietic system, including lymphoma, multiple myeloma, leukaemia, etc. They are highly malignant with a high incidence, a poor prognosis and a high mortality. Although the novel therapeutic strategies have partly improved the clinical efficacy of hematological malignancies, patients still face up with drug resistance, refractory disease and disease relapse. Many studies have shown that exosomes play an important role in hematological malignancies. Exosomes are nanoscale vesicles secreted by cells with a size ranging from 40 to 160 nm. They contain various intracellular components such as membrane proteins, lipids, and nucleic acids. These nanoscale vesicles transmit information between cells with the cargos. Thus, they participate in a variety of pathological processes such as angiogenesis, proliferation, metastasis, immunomodulation and drug resistance, which results in important role in the pathogenesis and progression of hematological malignancies. Furthermore, exosomes and the components carried in them can be used as potential biomarkers for the diagnosis, therapeutic sensitivity and prognosis in hematological malignancies. In the therapy of hematologic malignancies, certain exosome are potential to be used as therapeutic targets, meanwhile, exosomes are suitable drug carriers with lipid bilayer membrane and the nanostructure. Moreover, the tumor-derived exosomes of patients with hematologic malignancies can be developed into anti-tumor vaccines. The research and application of exosomes in hematological malignancies are summarized and discussed in this review.

Exosomes, a kind of nano-vesicles released by various cell types, carry a variety of "cargos" including proteins, RNAs, DNAs and lipids. There is substantial evidence that exosomes are involved in intercellular communication by exchanging "cargos" among cells and play important roles in cancer development. Because of the different expressions of "cargos" carried by exosomes in biological fluids under physiological and pathological conditions, exosomes have the potential as a minimally invasive method of liquid biopsy for cancer diagnosis and prognosis. In addition, due to their good biocompatibility, safety, biodistribution and low immunogenicity, exosomes also have potential applications in the development of promising cancer treatment methods. In this review, we summarize the recent progress in the isolation and characterization techniques of exosomes. Moreover, we review the biological functions of exosomes in regulating tumor metastasis, drug resistance and immune regulation during cancer development and outline the applications of exosomes in cancer therapy.

OBJECTIVE To explore the effect of pomalidomide on the maturation/activity of monocyte-derived dendritic cells（moDCs） in chronic myelogenous leukemia（CML） patients.METHODS Peripheral blood samples were collected from CML patients treated with long-term use of imatinib（n=10）, nilotinib（n=10） and dasatinib（n=9）, respectively. Monocyte-derived dendritic cells were cultured in vitro and treated with 10 μmol·L -1 pomalidomide or the same amount of drug solvent. The expression of maturation/activity related markers CD40, CD83 and HLA-DR on the surface of moDCs was detected by flow cytometry. The secretion of DC activity-related cytokines IL-6 and MIP-1α in the cell culture supernatant was detected by cytometric beads array.RESULTS Compared with the control group, the experiment group（pomalidomide group） significantly enhanced the expression ratio of the surface marker CD40, CD83 and HLA-DR on the CML patients’ moDCs treated with imatinib, nilotinib and dasatinib, respectively（all P＜0.05）. When analyzing the moDCs from all the 29 CML patients together, pomalidomide was also observed to significantly enhance the secretion concentration of IL-6 and MIP-1α compared with the control group（all P＜0.05）.CONCLUSION 10 μmol·L -1 pomalidomide can effectively promote the maturation/activity of CML patients’ moDCs treated with long-term use of imatinib, nilotinib and dasatinib, respectively in vitro, which is expected to be used as a promising DC adjuvant in DC-based immunotherapy strategies, such as DC anti-tumor vaccine and DC cell therapy.

Objective: Leonurine is a bioactive alkaloid compound extracted from Leonurus japonicus Houtt, which potentially has immunomodulatory effects. The immunomodulatory effect and mechanism of leonurine on monocyte derived dendritic cells (moDCs) from healthy donors (HDs) and multiple myeloma (MM) patients were investigated for the first time.Methods: Peripheral blood from HDs and MM patients was isolated for peripheral blood mononuclear cells (PBMCs). The generation of moDCs was conducted by the incubation of monocytes from PBMCs in the medium consisting of RPMI 1640 medium, 2 mmol/L L-glutamine, 5% human serum, 800 U/mL GM-CSF, 500 U/mL IL-4, 100 U/mL penicillin and 0.1 mg/mL streptomycin. During the incubation of 7 days, the cells were administrated with 1 μM leonurine or 1 × PBS as the control group. On the 8th day, cells were harvested. The expression of maturation associated surface markers CD40, CD83, and HLA-DR on moDCs was analyzed by flow cytometry. Moreover, moDCs with or without 1 μM leonurine administration were evaluated by LC-MS/MS for metabolomics which was further analyzed for the potential mechanism of leonurine on moDCs.Results: The proportion of moDCs in the harvested cells was significantly higher in the HD group (n = 14) than in the MM patient group (n = 11) (p = 0.000). Leonurine significantly enhanced the median fluorescence intensity of CD83, HLA-DR and CD40 expression on HD-moDCs (n = 14; p = 0.042, p = 0.013, p = 0.084) as well as MM paitent-moDCs (n = 11; p = 0.020, p = 0.006, p = 0.025). The metabolomics data showed that in moDCs (HD, n = 15), 18 metabolites in the pathway of arachidonic acid metabolism showed significant differences between the leonurine group and the control group (VIP all >1 and P all <0.05). To be specific, 6-Keto-PGE1, 8,9-DHET, 11 (R)-HETE, 12-Keto-LTB4, 12-OxoETE, 15 (S)-HETE, 15-Deoxy-Delta12,14-PGJ2, 15-Keto-PGF2a, 20-COOH-LTB4, Lecithin, PGA2, PGB2, PGE2, PGF2a, PGG2, Prostacyclin were significantly upregulated in the leonurine group than in the control group, while Arachidonic Acid and TXB2 were significantly downregulated in the leonurine group than in the control group.Conclusion: Leonurine significantly promotes the maturation of moDCs derived from HDs and MM patients, the mechanism of which is related to arachidonic acid metabolism.

The aim of this study was to explore the microecological distribution and differences in the uterus and vaginal microbiome in women with early embryonic arrest and those with normal pregnancy by high-throughput sequencing. We systematically sampled the vaginal and uterine microbiomes of 56 pregnant women, namely, 38 patients with early embryonic arrest and 18 pregnant women with normal pregnancy-induced abortion. We obtained colonization data by 16S rRNA gene amplicon sequencing. In the vagina, Lactobacillus, Bacteroidetes and Helicobacter exhibited significant differences between the groups. We further found that Lactobacillus iners, Lactobacillus crispatus, Lactobacillus gasseri and Lactobacillus jensenii were the most dominant Lactobacillus species and that L. iners was significantly different between the groups. Receiver operating characteristic (ROC) curve analysis confirmed that Ensifer had the highest predictive value for early embryonic arrest. In the uterine cavity, we determined that Proteobacteria, Bacteroidetes, Firmicutes and Actinobacteria were the dominant bacteria at the phylum level and that Bacteroides, Pseudarthrobacter, Lactobacillus and Ralstonia were the dominant genera. Further classification of Lactobacillus revealed that L. iners, L. crispatus, L. gasseri, and L. jensenii were the main species. There was a significant difference in L. jensenii between the normal pregnancy group and early embryonic arrest group. Random forest analysis revealed 18 different genera in the uterus, and ROC curve analysis indicated that Candidatus Symbiobacter, Odoribacter, Blautia, Nocardioides and Ileibacterium had a certain predictive value.

目的 观察单唾液酸四己糖神经节苷脂联合康复训练治疗脑卒中的临床疗效.方法 选取2018年1月—2021年2月在绵阳市中心医院接受治疗的脑卒中病人128例,采用随机数字表法分为观察组(63例)和对照组(65例).对照组采用常规治疗结合康复训练,观察组在对照组基础上联合单唾液酸四己糖神经节苷脂治疗,比较两组治疗前后血液流变学指标、美国国立卫生研究院卒中量表(NIHSS)评分、平衡与功能性步行能力、血清神经元特异性烯醇化酶(NSE)、中枢神经特异性蛋白(S100β)水平.结果 治疗后,观察组血液流变指标血浆黏度、全血高切黏度、全血低切黏度以及血清NSE、S100β水平均低于对照组(P<0.05);治疗后,观察组Berg平衡量表(BBS)、功能性步行量表(FAC)评分均高于对照组(P<0.001);治疗后第1周、第2周,观察组NIHSS评分均低于对照组(P<0.001).结论 单唾液酸四己糖神经节苷脂联合康复训练可明显改善脑卒中病人的平衡与功能性步行能力以及神经功能,促进病人血流动力学恢复正常.

OBJECTIVE:To investigate the effects of dasatinib on the maturation of monocyte-derived dendritic cells (moDCs) derived from healthy donors (HDs) and chronic myelogenous leukemia (CML) patients. METHODS:Peripheral blood mononuclear cells (PBMCs) were isolated from HDs (n=10) and CML patients (n=10) who had got the remission of MR4.5 with imatinib treatment. The generation of moDCs from PBMCs was completed after 7 days of incubation in DC I culture medium, and another 3 days of incubation in DC II culture medium with or without 25 nmol/L dasatinib. On the 10th day, cells were harvested and expression of molecules of maturation related marker were assessed by flow cytometry. The CD80+CD86+ cell population in total cells was gated as DCs in the fluorescence-activated cell storting (FACS) analyzing system, then the expression of CD83, CD40 or HLA-DR in this population was analyzed respectively. RESULTS:The proportion of CD80+CD86+ cells in total cells didn't show a statistical difference between HD group and patient group (89.46%±9.70% vs 87.39%±9.34%, P=0.690). Dasatinib significantly enhanced the expression of the surface marker CD40 (P=0.008) and HLA-DR (P=0.028) on moDCs derived from HDs compared with the control group, while the expression of CD83 on moDCs didn't show a significant difference between dasatinib group and the control group (P=0.428). Meanwhile, dasatinib significantly enhanced the expression of the surface marker CD40 (P=0.023), CD83 (P=0.038) and HLA-DR (P=0.001) on moDCs derived from patients compared with the control group. CONCLUSION:For CML patients, the same high proportion of moDCs as HDs can be induced in vitro, which provides a basis for the application of DC-based immunotherapy strategy. Dasatinib at the concentration of 25 nmol/L can efficiently promote the maturation of moDCs derived from HDs and CML patients in vitro. Dasatinib shows potential as a DC adjuvant to be applied in DC-based immunotherapy strategies, such as DC vaccine and DC cell-therapy.

Black phosphorus (BP) consists of phosphorus atoms, an essential element of bone and nucleic acid, which covalently bonds to three adjacent phosphorus atoms to form a puckered bilayer structure. With its anisotropy, band gap, biodegradability, and biocompatibility properties, BP is considered promising for cancer therapy. For example, BP under irradiation can convert near-infrared (NIR) light into heat and reactive oxygen species (ROS) to damage cancer cells, called photothermal therapy (PTT) and photodynamic therapy (PDT). Compared with PTT and PDT, the novel techniques of sonodynamic therapy (SDT) and photoacoustic therapy (PAT) exhibit amplified ROS generation and precise photoacoustic-shockwaves to enhance anticancer effect when BP receives ultrasound or NIR irradiation. Based on the prospective phototherapy, BP with irradiation can cause a "double-kill" to tumor cells, involving tumor-structure damage induced by heat, ROS, and shockwaves and a subsequent anticancer immune response induced by in situ vaccines construction in tumor site, which is referred to as photoimmunotherapy (PIT). In conclusion, BP shows promise in natural antitumor biological activity, biological imaging, drug delivery, PTT/PDT/SDT/PAT/PIT, nanovaccines, nanoadjuvants, and combination immunotherapy regimens.

纳米载体具有靶向递送药物至特定部位的潜力,因此纳米载体的开发一直受到广泛关注.近10年里,制备基于表面活性剂的纳米囊泡以改善药物递送,引起了研究者们的兴趣.类脂囊泡由非离子表面活性剂在水性介质中自组装形成,具有既能包裹亲水性化合物又能包裹亲脂性化合物的囊泡结构,广泛应用于各种给药途径.与脂质体相比,类脂囊泡不仅具有与其相似的优点,如既能装载亲水性药物又能装载亲脂性药物,而且类脂囊泡的制备方法更简单,制备原料价格更便宜,稳定性更好,克服了脂质体的主要缺点.本文综述了类脂囊泡各制备方法的优缺点及其在不同给药途径中的研究进展.

Background The purpose of this study was to evaluate the distributions of vaginal microbiome dysbiosis and human papillomavirus (HPV) subtypes in infertile women and explore the correlations of HPV infection and vaginal microbiome dysbiosis with infertility. Methods In total, 1464 women aged 18–50 years were included in this study; 649 participants were included in the infertility group, and 815 participants were included in the normal group. The participants were tested for HPV, and their vaginal microecology was examined. The χ 2 test and Spearman regression were used for statistical analysis, and binary logistic regression was performed to identify the risk factors for infertility. Results The patients in the infertility group were younger than those in the normal group, and the proportions of bacterial vaginosis and vaginal imbalance in the infertility group were significantly higher than those in the normal group. The incidence proportions of high-risk HPV types in the infertility group were significantly higher than those in the normal group, and the proportions of high-risk subtytes HPV16, HPV39, HV52, HPV56, and HPV68 were significantly higher in the infertility group than in the normal group. However, there were no significant differences in the incidences of low-risk HPV types. The incidence proportions of vaginal flora imbalance and HPV infection in the infertility group were significantly higher than those in the normal group. HPV16, HPV33, HPV51, HPV52and HPV58 infections were independent risk factors for infertility. Conclusions Vaginal microecological imbalance and HPV infection are directly related to infertility, and precautions should be taken.

Multiple myeloma (MM) is a hematological malignancy that is still incurable. The bone marrow microenvironment (BMM), with cellular and non-cellular components, can create a favorable environment for the survival, proliferation and migration of MM cells, which is the main reason for the failure of MM therapies. Many studies have demonstrated that exosomes play an important role in the tumor-supportive BMM. Exosomes are nanoscale vesicles that can be released by various cells. Some exosomes contribute to the pathogenesis and progression of MM. MM-derived exosomes act on different cells in the BMM, thereby creating an environment conducive to the survival and growth of MM cells. Owing to the important roles of exosomes in the BMM, targeting the secretion of exosomes may become an effective therapeutic strategy for MM. In addition, the abnormal expression of “cargos” in the exosomes of MM patients may be used to diagnose MM or used as part of a screen for the early prognoses of MM patients. Exosomes also have good biological properties, including safety, biocompatibility, stability and biodegradability. Therefore, the encapsulation of anti-cancer drugs in exosomes, along with surface modifications of exosomes with targeting molecules, are very promising strategies for cancer therapies—particularly for MM. In addition, DC-derived exosomes (DC-EXs) can express MHC-I, MHC-II and T cell costimulatory molecules. Therefore, DC-EXs may be used as a nanocarrier to deliver cancer vaccines in MM. This review summarizes the recent progress of exosome research regarding the pathogenesis of, diagnosis of, prognosis of and therapeutic strategies for MM.

2019年12月,全球范围爆发了新型冠状病毒(SARS-CoV-2)引发的传染性肺炎,由于SARS-CoV-2传染性强且无特效抗病毒药物,导致SARS-CoV-2迅速全球性蔓延,国内外专家积极投身于抗SARS-CoV-2的研究工作.我国李兰娟院士在体外实验中发现达芦那韦能显著抑制SARS-CoV-2复制,有望成为抗SARS-CoV-2的有效药.因此本文拟对达芦那韦的药理作用、药动学特点、合理使用与药学监护要点进行总结,并综述达芦那韦治疗新型冠状病毒的研究进展,以期为常态化防控SARS-CoV-2提供参考.

目的 探讨达卡巴嗪长循环脂质体(PEGylated dacarbazine liposome,PEG-DTIC-LP)的制备及体内抗肿瘤效应.方法 采用硫酸铵梯度法制备PEG-DTIC-LP,考察其包封率、载药量、形态、粒径、Zeta电位、稳定性、体外释药性等性质.建立荷黑色素瘤小鼠模型,将小鼠分为生理盐水组、空白脂质体组、DTIC溶液组、PEG-DTIC-LP组4组,每组6只,雌雄各半.于第1、3、5、7、9天按10 mg/kg给药剂量给生理盐水组小鼠尾静脉注射生理盐水,空白脂质体组尾静脉注射空白脂质体混悬液,DTIC溶液组尾静脉注射1mg/mL DTIC溶液,PEG-DTIC-LP组尾静脉注射1 mg/mL PEG-DTIC-LP混悬液.以肿瘤体积、小鼠体重、中位生存时间为评价指标,研究PEG-DTIC-LP的抗肿瘤效应.结果 制备的PEG-DTIC-LP为半透明乳白色有蓝色乳光的液体;包封率为(60.41±2.47)％,载药量为(5.95±0.24)％;平均粒径为190nm,Zeta电位为-53.8mY;放置7天后PEG-DTIC-LP包封率无显著变化(P＞0.05),放置14天后包封率下降明显(P＜0.05);PEG-DTIC-LP组荷瘤小鼠的肿瘤体积显著小于DTIC组与生理盐水组(P＜0.05),但与空白脂质体组比较差异无统计学意义(P＞0.05);中位生存时间PEG-DTIC-LP组＞空白脂质体组＞生理盐水组＞DTIC溶液组(P＜0.05);PEG-DTIC-LP组体重低于其余三组(P＜0.05).结论 将达卡巴嗪制备成长循环脂质体有利于提高其抗肿瘤效应.

国家卫生健康委员会颁布的《新型冠状病毒肺炎诊疗方案(试行第四版)》中指出,针对重型和危重型患者可使用肠道微生态调节剂维持肠道微生态平衡,预防继发细菌感染,但缺乏具体使用信息。益生菌是目前应用最广的肠道微生态调节剂,对不存在益生菌制剂使用禁忌证的新型冠状病毒肺炎重症患者,结合现有证据,临床可酌情使用益生菌制剂,可优先考虑使用在其他研究中有一定有效性和安全性证据的益生菌,告知患者正确服用的方法和服用时间,避免抗菌药物等对益生菌作用的影响,并注意监护益生菌潜在的感染风险。

Dasatinib has been discovered to obtain immunomodulatory effects in addition to the targeting effect towards BCR-ABL in chronic myelogenous leukemia (CML) patients. But the effect of dasatinib on dendritic cells (DCs) is still not fully understood. Objective To investigate the effect of dasatinib on the maturation of monocyte derived dendritic cells (moDCs) from healthy donors (HDs) and CML patients. Method Peripheral blood mononuclear cells (PBMCs) were isolated from HDs (n=14) and CML patients (n=14) who had got remission of MR4.5 with imatinib treatment. The generation of moDCs was completed after 7 days of incubation in DC I medium, and another 3 days of incubation in DC II medium with or without 25nM dasatinib. On the 10th day, the moDCs were harvested and analyzed for the expression of surface markers CD83, CD80, CD86, CD40 and HLA-DR to reflect the maturation of the moDCs by flow cytometry. Results When analyzing the moDCs from all the 14 HDs together, dasatinib significantly enhanced the expression levels of the surface marker CD83 (P=0.039), CD40 (P=0.002) and HLA-DR (P=0.000) on moDCs compared with the control group, but there was no statistically significant difference in CD80 (P=0.073) and CD86 (P=0.897). Differently, when analyzing the moDCs derived from all the 14 patients together, there was no statistically significant difference in the expression levels of CD80 (P=0.086), CD86 (P=0.166), CD83 (P=0.674), CD40 (P=0.574) and HLA-DR (P=0.561) on moDCs between the dasatinib group and the control group. However, moDCs derived from 3 of the 14 patients show the enhanced expression of all the five surface makers with dasatinib administration compared to the control group. Besides, the moDCs derived from 6 of the 14 patients show the enhanced expression of at least one of the five surface markers. Notably, compared with moDCs derived from HD group (n=14), moDCs from patient group (n=14) express lower levels of CD80 (P=0.340), CD86 (P=0.007), CD40 (P=0.010), CD83 (P=0.019) and HLA-DR (P=0.036). Conclusion Dasatinib at the concentration of 25nM can efficiently promote the maturation of HD-derived moDCs in vitro, whereas this effect only occurs in part of the CML patients. And the moDCs from patients generally show much lower levels of the maturation associated surface makers compared with moDCs from HDs. Dasatinib shows potential as a DC adjuvant to be applied in DC-based therapeutic strategies, such as DC vaccine and DC cell-therapy. Disclosures No relevant conflicts of interest to declare.